Registered title, quoted from ClinicalTrials.gov
Efficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin A
An open trial on aplastic anaemia, registered on ClinicalTrials.gov. Led by Peking Union Medical College Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06802055, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
Inclusion criterion 8
At least one of the following criteria met at enrollment: hemoglobin < 100 g/L, platelets < 50 × 10⁹/L, or neutrophils < 1.0 × 10⁹/L;
Inclusion criterion 3
Paroxysmal nocturnal hemoglobinuria (PNH) clone ≥ 50%;
Exclusion criterion 3
Active infections with HIV, HCV, or HBV, liver cirrhosis, portal hypertension;
Exclusion criterion 8
Any concurrent malignancy within the past 5 years, except for localized basal cell carcinoma of the skin;
Exclusion criterion 9
Not pregnant or breastfeeding;
Inclusion criterion 6
Pregnant or breastfeeding women;
Exclusion criterion 11
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06802055, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age ≥ 18 years;
- Diagnosed with acquired aplastic anemia (AA), excluding congenital AA;
- At least one of the following criteria met at enrollment: hemoglobin < 100 g/L, platelets < 50 × 10⁹/L, or neutrophils < 1.0 × 10⁹/L;
- At enrollment, meeting at least one of the following conditions:
① Cyclosporine A (CsA) ineffective: (CsA) used for at least 3 months without achieving partial response (PR), or disease relapse occurred;
② CsA intolerant: Unsuitable for standard dose CsA treatment due to adverse events or underlying conditions.
- No active infections;
- Not pregnant or breastfeeding;
- Willing to sign the consent form;
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
Exclusion Criteria:
- Pancytopenia caused by other reasons, such as myelodysplastic syndrome (MDS);
- Evidence of clonal hematopoietic system bone marrow diseases (e.g., MDS or acute myeloid leukemia, AML);
- Paroxysmal nocturnal hemoglobinuria (PNH) clone ≥ 50%;
- History of hematopoietic stem cell transplantation (HSCT) before enrollment;
- Previous use of sirolimus or allergy to sirolimus;
- Severe adverse events to CsA in the past, making it unsuitable for reuse;
- Uncontrolled infection or bleeding with standard treatment;
- Active infections with HIV, HCV, or HBV, liver cirrhosis, portal hypertension;
- Any concurrent malignancy within the past 5 years, except for localized basal cell carcinoma of the skin;
- History of thromboembolic events, myocardial infarction, or stroke (including antiphospholipid antibody syndrome), or current use of anticoagulants;
- Pregnant or breastfeeding women;
- Participation in other clinical trials within the past 3 months.
Quoted from ClinicalTrials.gov, NCT06802055, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06802055, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.